There are limited options for tailored therapies for TNBC, which is the most aggressive subtype and is, therefore, treated either by chemotherapy with or without immune checkpoint inhibitors, and recently, with novel antibody–drug conjugates, e.g. sacituzumab govitecan or trastuzumab deruxtecan for HER2-low tumours. This evidence concerns the gene ERBB2 and neoplasm.